Advanced Diagnostic & Interventional Radiology Research Center | Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2 positive breast cancer patients: a randomized, phase III, equivalency clinical trial (BMC Cancer

Advanced Diagnostic & Interventional Radiology Research Center | Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2 positive breast cancer patients: a randomized, phase III, equivalency clinical trial (BMC Cancer
| Dec 9 2025
logo

Advanced Diagnostic & Interventional Radiology Research Center

scientific researches

  • Release Date : Jul 21 2024 - 08:09
  • : 133
  • Study time : Less than one minute

Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2 positive breast cancer patients: a randomized, phase III, equivalency clinical trial (BMC Cancer

HER2-positive breast cancer patients: {faces}

Following publication of the original article [], the authors identified that Behrouz Najafi was omitted as the third author in the author group. The author group in this correction article has been updated and the original article [] has been corrected.

  • Article_DOI : https://doi.org/10.1186/s12885-022-09895-5
  • Author(s) : abolghasem allahyari,ali ehsanpour,behrouz najafi
  • News Group : research,research article
  • News Code : 277952
مدیر سایت
Author:

مدیر سایت

0 Comments for this article

comment

Post your comment:

متن درون تصویر را در جعبه متن زیر وارد نمائید *
Enter your desired term to search
Theme settings